SPARC-LINCT07785102
Single Day of Ultra-accelerated TMS With a Single Dose of NRX-101
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Recruitment opened
- Start date changed from estimate of Sep 1, 2026 to Oct 1, 2026
- Site details revised
- Notable Eligibility criteria expanded, about 19 words
- Secondary endpoints: details revised at 2 of 2 entries
- Publications: details revised at 4 of 4 entries
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Change in Montgomery-Åsberg Depression Rating Scale (MADRS)
Timeframe: From day of treatment to six weeks after treatment
Secondary (2)
Hamilton Depression Rating Scale (HAM-D)
Patient Health Questionnaire 9-item (PHQ-9)
Arms and interventions
Open-label TMS + NRX-101Experimental
20 sessions of active iTBS combined with a single dose of NRX-101
Devices: TMS
Drugs: NRX-101
Sites
1 site in 1 country
- McLean HospitalBelmont, Massachusetts, United States